Logo

Samsung Bioepis & Celltrion Report Results of CT-P13 and SB2 (biosimilar, infliximab) in Prospective Study for the Treatment of Inflammatory Bowel Disease

Share this
Samsung Bioepis & Celltrion Report Results of CT-P13 and SB2 (biosimilar, infliximab) in Prospective Study for the Treatment of Inflammatory Bowel Disease

Samsung Bioepis & Celltrion Report Results of CT-P13 and SB2 (biosimilar, infliximab) in Prospective Study for the Treatment of Inflammatory Bowel Disease

Shots:

  • The new study showed that multiple switches b/w infliximab biosimilars CT-P13 & SB2 and the reference infliximab were found to be safe & effective for IBD. The study was published in Inflammatory Bowel Diseases
  • Patients with multiple switch group/ CT-P13 to SB2/reference infliximab to CT-P13 group showed clinical remission (76.9%/65.7%/76.9%); treatment persistence (85%/87.0%/70.1%) @12mos.; new ADAs after switch (0%/3.8%/3.7%); discontinued treatment due to active disease & sustained remission (8.7% & 8.7%/8.8% & 1.3%/14.8% & 22.2%); due to AEs (2.9%/3.8%/14.8%)
  • Additionally, no significant differences in the rate of remission @12mos, patients switched from CT-P13 to SB2 had a lower rate of clinical remission over the other 2 groups

Ref: The Center For Biosimilar | Image: Celltrion

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions